No abstract available.
Drug Therapy* ; Hypertension*

OBJECTIVETo investigate the current practice of pulmonary hypertension including current epidemiology, diagnosis and treatment.

DATA SOURCESThe review was based on data obtained from the published articles and guidelines.

STUDY SELECTIONArticles with high level of evidence or current best evidence in each issue were selected to be reviewed.

RESULTSOverall prevalence of pulmonary hypertension was 0.3% to 6% with left heart disease occupying the most proportion, followed by pulmonary disease, pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. In diagnosis, a flow diagram of diagnosis of pulmonary hypertension, differential diagnosis of pulmonary hypertension and how to determine the severity of pulmonary hypertension are explained including recent development of magnetic resonance imaging and gene abnormality study on bone morphogenetic protein receptor II. In treatment, newly-developed pulmonary vasodilators and the way to use them are shown to treat pulmonary hypertension.

CONCLUSIONSafer and more effective treatment algorithm and basic researches and clinical trials are warranted to be explored.

Humans ; Hyperaldosteronism/surgery* ; Hypertension/drug therapy* ; Technology

Humans ; Hypertension, Pulmonary/drug therapy* ; Antihypertensive Agents/therapeutic use* ; Cardiology ; Hypertension/drug therapy*

Evidence-Based Medicine ; Humans ; Hypertension ; drug therapy ; prevention & control

Humans ; Hypertension ; drug therapy ; Medicine, Chinese Traditional ; methods

In 2013 and 2014, many guidelines regarding the management of hypertension were released from various worldwide professional bodies. These guidelines are similar in their recommendations, but some differences are evident due to different choices and interpretations of evidence from clinical trials used in setting the guidelines. A noticeable change that is common to all the guidelines is an increase in the target blood pressure for the treatment of hypertension to 140/90 mmHg. The guidelines also introduce invasive approaches, such as renal sympathetic denervation, as additional measures to better manage resistant hypertension. This review gives a summary of recent guidelines from North America, Europe, and Asia for the management of hypertension, with a focus on pharmacological treatment, and compares these guidelines with the Korean guidelines.
Asia ; Blood Pressure ; Drug Therapy* ; Europe ; Hypertension ; North America ; Sympathectomy

Antihypertensive Agents/therapeutic use* ; Humans ; Hypertension/drug therapy*

Asians ; China ; Humans ; Hypertension/drug therapy* ; Practice Guidelines as Topic ; Writing

Antihypertensive Agents/therapeutic use* ; China ; Humans ; Hypertension/drug therapy* ; Research